Synthesis and Evaluation of<sup>111</sup>In-DOTA-mAb109 Monoclonal Antibody for Potential SPECT Molecular Imaging

朱华,; 李囡,; 张宏,; 林新峰,; 李振甫,; 杨志,

doi:10.6023/a14120832

Cited by 2 publications

(2 citation statements)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mAb109 or a nonspecific IgG antibody was conjugated with NCS-Bz-NOTA at a molar ratio of 1:10 and pH of 8.3 for 4 h as previously reported [ 15 ]. The final products (NOTA-mAb109) were purified by PD-10 size-exclusion columns using phosphate- buffered saline (PBS) as the mobile phase to remove unbound NCS-Bz-NOTA.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Zhu

Liu

et al. 2019

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

Monoclonal antibodies are believed to be magic bullets and hold great potential for lots of biological process. About 100 μg of mAb109 was expressed in 5 × 10 6 cells after 10 days’ immunization. 64 Cu-NOTA-mAb109 was synthesized with the specific activity of 0.74 MBq/μg and high in vitro stability. The binding affinity of 64 Cu-NOTA-mAb109 in A549 cells was determined to be 29.64 nM. 64 Cu-NOTA-mAb109 displayed prominent tumor accumulation from 2 h to 60 h p.i. (9.34 ± 0.67 %ID/g). NIRF imaging of Cy5.5-mAb109 showed high accumulation till 9 days p.i., while tumors nearly can not be observed in negative groups, which was confirmed by autoradiography. Immunohistological study confirmed that mAb109 had strong and specific capacity to bind lung adenocarcinoma (concentration to 58 nM). Our study demonstrated mAb109 was a new platform for the development of novel agent for lung adenocarcinoma noninvasive imaging. The resulted 64 Cu-NOTA-mAb109/Cy5.5-mAb109 show favorable imaging properties/specificity for A549 tumor and high sensitivity to human lung adenocarcinoma tissues.

show abstract

Section: Methodsmentioning

confidence: 99%

“…However, the significance of Prdx I in lung cancer progression and recurrence has not been fully investigated. We previously reported the preliminary results of 111 In-labeled mAb109 antibody for the imaging of Prdx I overexpression tumor [ 15 ]. PET nuclides are another good choice for acquiring high-quality images.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Zhu

Liu

et al. 2019

Acta Pharmacol Sin

Self Cite

View full text Add to dashboard Cite

show abstract

China’s radiopharmaceuticals on expressway: 2014–2021

et al. 2022

View full text Add to dashboard Cite

This review provides an essential overview on the progress of rapidly-developing China’s radiopharmaceuticals in recent years (2014–2021). Our discussion reflects on efforts to develop potential, preclinical, and in-clinical radiopharmaceuticals including the following areas: (1) brain imaging agents, (2) cardiovascular imaging agents, (3) infection and inflammation imaging agents, (4) tumor radiopharmaceuticals, and (5) boron delivery agents (a class of radiopharmaceutical prodrug) for neutron capture therapy. Especially, the progress in basic research, including new radiolabeling methodology, is highlighted from a standpoint of radiopharmaceutical chemistry. Meanwhile, we briefly reflect on the recent major events related to radiopharmaceuticals along with the distribution of major R&D forces (universities, institutions, facilities, and companies), clinical study status, and national regulatory supports. We conclude with a brief commentary on remaining limitations and emerging opportunities for China’s radiopharmaceuticals.

show abstract

Synthesis and Evaluation of¹¹¹In-DOTA-mAb109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Cited by 2 publications

References 8 publications

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

China’s radiopharmaceuticals on expressway: 2014–2021

Contact Info

Product

Resources

About

Synthesis and Evaluation of111In-DOTA-mAb109 Monoclonal Antibody for Potential SPECT Molecular Imaging

Cited by 2 publications

References 8 publications

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

China’s radiopharmaceuticals on expressway: 2014–2021

Contact Info

Product

Resources

About

Synthesis and Evaluation of¹¹¹In-DOTA-mAb109 Monoclonal Antibody for Potential SPECT Molecular Imaging